- Articles Online
- About Journal
- For Authors
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Articles Online
- Online First
- Current issue
- Archive
- Collections
- Special Issues
- About Journal
- About the Journal
- Editorial Board
- Awards
- Inclusion
- Subscriptions
- For Authors
- Editorial Policy
- Manuscript Review
- Ethical Review
- Interest Conflict
- Data Sharing
- Contact Us
- Interest Conflict
- Charge and Payments
- Data Sharing
Type I and Ⅱ Cardiorenal Syndrome-related Biomarkers
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 20, Pages: 222-228(2019)
- 作者机构：
1.天津中医药大学 第一附属医院，天津 300000；
2.天津中医药大学，天津 300000
- 作者简介：
- 基金信息：
DOI：10.13422/j.cnki.syfjx.20191328
CLC： R22; R242; R2-031; R285.5; R287Received：16 October 2018，
Published Online：20 March 2019，
Published：20 October 2019
- 稿件说明：
移动端阅览
Meng-meng WANG, Dong-xue QIAO, Xin GAO, et al. Type I and Ⅱ Cardiorenal Syndrome-related Biomarkers[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(20): 222-228.
Meng-meng WANG, Dong-xue QIAO, Xin GAO, et al. Type I and Ⅱ Cardiorenal Syndrome-related Biomarkers[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(20): 222-228. DOI： 10.13422/j.cnki.syfjx.20191328.
摘要
心脏和肾脏的生理病理相互依存，相互影响，其中任何一个器官的功能障碍导致另一个器官的功能障碍，即为心肾综合征，以Ⅰ型和Ⅱ型的发病率最高，临床最为常见。中医对心肾同病的认识历史悠久，认为本病的病位在心和肾，采用温阳益气，活血利水等方法治疗，有效改善了患者的心肾功能。然而，心肾综合征发生的病理机制复杂，且临床表现多样，导致对疾病早期的临床诊疗较为困难，从而错过最佳干预时机，使疾病预后不良。生物标志物在预测心肾综合征的发生、发展方面发挥着至关重要的作用，因此，寻找特异性和敏感性较好的生物标志物，准确评价心脏和肾脏生理病理的变化，以达到对心肾综合征的早期诊断、早期干预，提升疾病诊疗效果的目的。目前，国内外学者研究和应用较多的标志物主要集中于肾小管损伤，包括中性粒细胞明胶酶相关载脂蛋白、肾损伤因子-1，尿白细胞介素-18等。此外，还有一些其他研究成果，细胞周期阻滞诱导因子如胰岛素样生长因子结合蛋白7，金属蛋白酶组织抑制因子-2，以及与矿物质代谢相关的成纤维细胞生长因子23等。这些生物标志物在机体内含量升高的时间都早于血清肌酐升高的时间，能较好地预测早期心肾综合征的发生，有较高的应用价值和研究价值。通过对国内外文献中Ⅰ型和Ⅱ型心肾综合征的相关生物标志物进行总结，筛选出了几种具有代表性的标志物的研究进展进行综述，为相关研究提供参考。
Abstract
The physiology and pathology of the heart and kidney are interdependent and interact with each other
and dysfunction of any one of them causes dysfunction of the other
namely cardiorenal syndrome
in which type I and type Ⅱ have the highest incidence rate and are the commonest in clinic. Traditional Chinese medicine has a long history of treating the cardiorenal syndrome. It believes that the disease is located in the heart and kidney
and Wenyang Yiqi
Huoxue Lishui and other methods shall be adopted to effectively improve the heart and kidney function of patients. However
the pathogenesis of cardiorenal syndrome is complicated
and the clinical manifestations are diverse
which makes it difficult to diagnose and treat in the early stage
and causes missing of the best intervention timing and a poor prognosis. Biomarkers play a vital role in predicting the occurrence and development of cardiorenal syndrome. Therefore
efforts shall be made to look for biomarkers with better specificity and sensitivity
accurately evaluate physiological and pathological changes in heart and kidney
so as to achieve early diagnosis and early intervention of cardiorenal syndrome
and improve the effect of disease diagnosis and treatment. At present
domestic and foreign scholars have studied and applied more markers mainly in renal tubular injury
including neutrophil gelatinase-associated lipocalin
kidney injury molecule-1 and urinary interleukin-18. In addition
other studies have found cell cycle arrest inducing factors
such as insulin-like growth factor binding protein 7
tissue inhibitor metallo proteinase-2
and fibroblast growth factor 23 associated with mineral metabolism. The increase of the content of these biomarkers in the body is earlier than the rise of serum creatinine
which can better predict the occurrence of early cardiorenal syndrome
and has a high application value and research value. After summarization of the biomarkers relating to type I and Ⅱ cardiorenal syndrome in domestic and foreign literatures
the research progress of several representative markers were reviewed to provide reference for related research.
关键词
Keywords
references
Forman D E , Butler J , WANG Y , et al . Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure [J]. J Am Coll Cardiol , 2004 , 43 ( 1 ): 61 - 67
Gannon S A , Mukamal K J , CHANG J D , et al . Echocardiographic predictors of change in renal function with intravenous diuresis for decompensated heart failure [J]. ESC Heart Fail , 2018 , 5 ( 5 ): 858 - 863 .
Cruz D N , Bagshaw S M . Heart-kidney interaction: epidemiology of cardiorenal syndromes [J]. Int J Nephrol , 2011 , 2011 : 351291 .
Ronco C , Cicoira M , McCullough P A . Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure [J]. J Am Coll Cardiol , 2012 , 60 ( 12 ): 1031 - 1042 .
Go A S , Chertow G M , FAN D , et al . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J]. N Engl J Med , 2004 , 351 ( 13 ): 1296 - 1305 .
Sarnak M J , Levey A S , Schoolwerth A C , et al . Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention [J]. Hypertension , 2003 , 42 ( 5 ): 1050 - 1065 .
Hillege H L , Nitsch D , Pfeffer M A , et al . Renal function as a predictor of outcome in a broad spectrum of patients with heart failure [J]. Circulation , 2006 , 113 ( 5 ): 671 - 678 .
SHAO Q , XIA Y , ZHAO M , et al . Effectiveness and safety of peritoneal dialysis treatment in patients with refractory congestive heart failure due to chronic cardiorenal syndrome [J]. Biomed Res Int , 2018 , 2018 : 6529283 .
张蕾 ， 史耀勋 ． 温通化浊法治疗慢性心肾综合征的机理探讨 [J]． 中西医结合心血管病电子杂志 ， 2018 ， 6 ( 21 )： 41 ．
王海霞 ， 牛燕运 ． 温阳益气活血法对Ⅱ型心肾综合征病人心功能及肾功能的影响 [J]． 中西医结合心脑血管病杂志 ， 2018 ， 16 ( 17 )： 2537 - 2539 ．
张艳 ， 杨继 ， 冯伟 ， 等 ． 益气调心汤治疗心肾综合征患者疗效观察 [J]． 现代中西医结合杂志 ， 2018 ， 27 ( 35 )： 3895-3897，3902 ．
Ronco C , Mocullough P , Anker S D , et al . Cardiorenal syndromes: report from the consensus conference of the acute dialysis quality initiative [J]. Eur Heart J , 2010 , 31 ( 6 ): 703 - 711 .
Atici A , Emet S , Cakmak R , et al . Type I cardiorenal syndrome in patients with acutely decompensated heart failure: the importance of new renal biomarkers [J]. Eur Rev Med Pharmacol Sci , 2018 , 22 ( 11 ): 3534 - 3543 .
Bongartz L G , Cramer M J , Doevendans P A , et al . The severe cardiorenal syndrome: 'Guyton revisited' [J]. Eur Heart J , 2004 , 26 ( 1 ): 11 - 17 .
Ronco C , Haapio M , House A A , et al . Cardiorenal syndrome [J]. J Am Coll Cardiol , 2008 , 52 ( 19 ): 1527 - 1539 .
Virzi G M , Breglia A , Brocca A , et al . Levels of proinflammatory cytokines, oxidative stress, and tissue damage markers in patients with acute heart failure with and without cardiorenal syndrome type 1 [J]. Cardiorenal Med , 2018 , 8 ( 4 ): 321 - 331 .
Leithe M E , Margorien R D , Hermiller J B , et al . Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure [J]. Circulation , 1984 , 69 ( 1 ): 57 - 64 .
Smilde T D , Damman K , Van der Harst P , et al . Differential associations between renal function and “modifiable” risk factors in patients with chronic heart failure [J]. Clin Res Cardiol , 2009 , 98 ( 2 ): 121 - 129 .
Martins J L , Santos L , Faustino A , et al . Worsening or ‘pseudo-worsening’ renal function? The prognostic value of hemoconcentration in patients admitted with acute heart failure [J]. Rev Port Cardiol , 2018 , 37 ( 7 ): 595 - 602 .
Lingart C , Ulrich C , Greinert D , et al . Systemic inflammation in acute cardiorenal syndrome: an observational pilot study [J]. ESC Heart Fail , 2018 , 5 ( 5 ): 920 - 930 .
Haase M , Müller C , Damman K , et al . Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI) [J]. Contrib Nephrol , 2013 , 182 : 99 - 116 .
Silverberg D , Wexler D , Blum M , et al . The association between congestive heart failure and chronic renal disease [J]. Curr Opin Nephrol Hypertens , 2004 , 13 ( 2 ): 163 - 170 .
Kielstein J T , Bode-Boger S M , Klein G , et al . Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure [J]. Eur J Clin Invest , 2003 , 33 ( 5 ): 370 - 375 .
Zebrack J S , Anderson J L , Beddhu S , et al . Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? [J]. J Am Coll Cardiol , 2003 , 42 ( 1 ): 57 - 63 .
Deswal A , Petersen N J , Feldman A M , et al . Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST) [J]. Circulation , 2001 , 103 ( 16 ): 2055 - 2059 .
Rauchhaus M , Doehner W , Francis D P , et al . Plasma cytokine parameters and mortality in patients with chronic heart failure [J]. Circulation , 2000 , 102 ( 25 ): 3060 - 3067 .
Levine B , Kalman J , Mayer L , et al . Elevated circulating levels of tumor necrosis factor in severe chronic heart failure [J]. N Engl J Med , 1990 , 323 ( 4 ): 236 - 241 .
Torre-Amione G , Kapadia S , Benedict C , et al . Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction(SOLVD) [J]. J Am Coll Cardiol , 1996 , 27 ( 5 ): 1201 - 1206 .
Savira F , CAO L , WANG I , et al . Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: implications for cardiorenal syndrome [J]. PLoS One , 2017 , 12 ( 11 ): e0187459 .
CHEN H Y , CHOU C , CHANG C H , et al . Urine cofilin-1 detection for predicting type 1 cardiorenal syndrome in the coronary care unit: a gold nanoparticle-and laser-based approach [J]. Cardiorenal Med , 2018 , 8 ( 4 ): 302 - 310 .
Perrone R D , Madias N E , Levey A S . Serum creatinine as an index of renal function: new insights into old concepts [J]. Clin Chem , 1992 , 38 ( 10 ): 1933 - 1953 .
Briguori C , Visconti G , Rivera N V , et al . Cystatin C and contrast-induced acute kidney injury [J]. Circulation , 2010 , 121 ( 19 ): 2117 - 2122 .
Gevorgyan E M M , Voronina N P , Goncharova O N V , et al . Cystatin C as a marker of progressing cardiovascular events during coronary heart disease [J]. Bull Exp Biol Med , 2017 , 162 ( 4 ): 421 - 424 .
DUAN X , YAN F , HU H , et al . Qiliqiangxin protects against renal injury in rat with cardiorenal syndrome type I through regulating the inflammatory and oxidative stress signaling [J]. Biol Pharm Bull , 2018 , 41 ( 8 ): 1178 - 1785 .
Nielsen B S , Borregaard N , Bundgaard J R , et al . Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases [J]. Gut , 1996 , 38 ( 3 ): 414 - 420 .
Brisco M A , Testani J M . Novel renal biomarkers to assess cardiorenal syndrome [J]. Curr Heart Fail Rep , 2014 , 11 ( 4 ): 485 - 499 .
Mccullough P A , Shaw A D , Haase M , et al . Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference [J]. Contrib Nephrol , 2013 , 182 : 13 - 29 .
ZHANG A , CAI Y , WANG P F , et al . Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and Meta-analysis [J]. Crit Care , 2016 , 20 : 41 .
Cruz D N , Goh C Y , Haase-fielitz A , et al . Early biomarkers of renal injury [J]. Congest Heart Fail , 2010 , 16 ( 1 ): 25 - 31 .
GAN J , ZHOU X . Comparison of urine neutrophil gelatinase-associated lipocalin and interleukin-18 in prediction of acute kidney injury in adults [J]. Medicine , 2018 , 97 ( 39 ): e12570 .
Ichimura T , Bonventre J V , Bailly V , et al . Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury [J]. J Biol Chem , 1998 , 273 ( 7 ): 4135 - 4142 .
HAN W K , Bailly V , Abichandani R , et al . Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury [J]. Kidney Int , 2002 , 62 ( 1 ): 237 - 244 .
Haque M E , Khan F , CHI L , et al . A phage display-identified peptide selectively binds to kidney injury molecule-1 (KIM-1) and detects KIM-1-overexpressing tumors in vivo [J]. Cancer Res Treat , 2018 .
HAN W K , Waikar S S , Johnson A , et al . Urinary biomarkers in the early diagnosis of acute kidney injury [J]. Kidney Int , 2008 , 73 ( 7 ): 863 - 869 .
Damman K , Masson S , Hillege H L , et al . Clinical outcome of renal tubular damage in chronic heart failure [J]. Eur Heart J , 2011 , 32 ( 21 ): 2705 - 2712 .
Velho G , Bouby N , Hadjadj S , et al . Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria [J]. Diabetes Care , 2013 , 36 ( 11 ): 3639 - 3645 .
Engelbertz C , Brand E , Fobker M , et al . Elevated copeptin is a prognostic factor for mortality even in patients with renal dysfunction [J]. Int J Cardiol , 2016 , 221 : 327 - 332 .
Meijer E , Bakker S J , Halbesma N , et al . Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort [J]. Kidney Int , 2010 , 77 ( 1 ): 29 - 36 .
SHENG X , LIN L , GUO F , et al . Copeptin level in the early prediction of cardiorenal syndrome in rats [J]. Exp Ther Med , 2018 , 16 ( 2 ): 937 - 944 .
Kashani K , Al-khafaji A , Ardiles T , et al . Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury [J]. Critical Care , 2013 , 17 ( 1 ): R25 .
Hoste E A , Mccullough P A , Kashanl K , et al . Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers [J]. Nephrol Dial Transplant , 2014 , 29 ( 11 ): 2054 - 2061 .
Kobori H , Nangaku M , Navar L G , et al . The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease [J]. Pharmacol Rev , 2007 , 59 ( 3 ): 251 - 287 .
YANG X , CHEN C , TIAN J , et al . Urinary angiotensinogen level predicts AKI in acute decompensated heart failure: a prospective, two-stage study [J]. J Am Soc Nephrol , 2015 , 26 ( 8 ): 2032 - 2041 .
CHEN C , YANG X , LEI Y , et al . Urinary biomarkers at the time of AKI diagnosis as predictors of progression of AKI among patients with acute cardiorenal syndrome [J]. Clin J Am Soc Nephrol , 2016 , 11 ( 9 ): 1536 - 1544 .
Yamamoto T , Yamamoto A , Watanabe M , et al . Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues [J]. Biotechnol Lett , 2009 , 31 ( 11 ): 1695 - 1701 .
Kamijo A , Sugaya T , Hikawa A , et al . Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules [J]. Am J Pathol , 2004 , 165 ( 4 ): 1243 - 1255 .
Hishikari K , Hikita H , Nakamura S , et al . Urinary liver-type fatty acid-binding protein level as a predictive biomarker of acute kidney injury in patients with acute decompensated heart failure [J]. Cardiorenal Med , 2017 , 7 ( 4 ): 267 - 275 .
Gattineni J , Baum M . Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism [J]. Pediatr Nephrol , 2010 , 25 ( 4 ): 591 - 601 .
Leaf D E , Wolf M , Stern L . Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury [J]. Nephrol Dial Transplant , 2010 , 25 ( 4 ): 1335 - 1337 .
Ginsberg C , Craven T E , Chonchol M B , et al . PTH, FGF23, and intensive blood pressure lowering in chronic kidney disease participants in SPRINT [J]. Clin J Am Soc Nephrol , 2018 , doi: 10.2215/CJN.05390518 http://doi.org/10.2215/CJN.05390518 .
DieplingerI B , Egger M , Haltmltmayer M , et al . Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study [J]. Clin Chem , 2014 , 60 ( 3 ): 530 - 540 .
CHANG C H , YANG C H , YANG H Y , et al . Urinary biomarkers improve the diagnosis of intrinsic acute kidney injury in coronary care units [J]. Medicine , 2015 , 94 ( 40 ): e1703 .
0
Views
13
下载量
0
CSCD
- L-PDFDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
AI问答- Postal code：100700
- Tel：010-84076882 Email：syfjx_2010@188.com
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
